• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Invitae | Genelex

Invitae | Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • For Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
  • For Providers
    • Conditions
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • Contact Us
  • Log In
Home / Test Menu / ADRA2A

ADRA2A Genotyping

Genelex ADRA2A GenotypingAdrenoceptor Alpha 2A (ADRA2A) is a gene that encodes for receptors that are widely distributed within the central nervous system and periphery. Studies have shown ADRA2A variations to be associated with the effectiveness of methylphenidate (Ritalin®), a medication used to treat symptoms of attention deficit hyperactivity disorder (ADHD) [37]. The most well-studied variant of the ADRA2A gene has been found to be present in nearly 25% of the Caucasian population.

Adrenoceptors play a critical role in regulating neurotransmitter release from sympathetic nerves and from neurons that release the hormone and neurotransmitter norepinephrine in the central nervous system. ADRA2A is localized on sympathetic nerves in the brainstem, midbrain, hypothalamus, hippocampus, spinal cord, cerebral cortex, cerebellum, and septum.

Although the mechanism of action for methylphenidate in ADHD is not fully understood, one purposed mechanism is increased norepinephrine tone in the prefrontal cortex by binding to the ADRA2A receptor. The genetic variation to this receptor may contribute to methylphenidate (Ritalin®) and dexmethylphenidate (Focalin®) response. Genetic variant tested is c.-1252G>C (rs1800544).

Indications for ADRA2A Testing

Patients with ADHD that are on or are considering starting methylphenidate or dexmethylphenidate may be candidates for ADRA2A testing. Generally, assessment of medical necessity for testing is up to the provider’s clinical judgment.

Insurance Coverage

Check with your insurance to see if ADRA2A genotyping is covered. CPT Codes is 81479 (provided as guidance only).

Specimen Collection

Click here to order testing supplies or call Client Services at 800-837–8362.

  • Buccal Swabs: 4 sterile buccal swabs
  • Blood: 5-10cc whole blood lavender-top EDTA or yellow-top ACD-A tubes
  • Turnaround Time: 10 business days, faster turnaround available for clinical trials

Individual Genes Tested

CYP2C9
CYP2C19
CYP2D6
CYP3A4 / CYP3A5
ADRA2A
CYP1A2
CYP2B6
CYP4F2 / VKORC1
COMT
DPYD
Factor II - Factor V Leiden
GRIK4
HLA-A or HLA-B
HTR2A
HTR2C
IFNL3
MTHFR
NAT2
OPRM1
SLCO1B1
TPMT
UGT1A1

Improving Drug Efficacy

Genelex's pharmacogenetic testing bridges the gap in understanding how the role of PGx can help in patient care and offers a simple DNA test and provides you with a report of the results that you and your doctor can discuss.

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
FAQs
References

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Contact Us
Privacy Practices
Privacy Policy

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.